 |
(Photo=Hanmi Science) |
[Alpha Biz= Reporter Kim Jisun] Hanmi Science, the holding company of Hanmi Group, will retire more than 1.56 million shares of its own to enhance shareholder value.
Hanmi Science said on the 4th that it held its first board meeting after a shareholders' meeting at its headquarters in Songpa-gu, Seoul, and decided to retire and appoint a co-CEO. On this day, the board of directors appointed Im Jong-hoon as the new CEO and confirmed the co-CEO system with the existing CEO Song Young-sook.
The board of directors also discussed changing and establishing the company's work, position, and compensation system, establishing a welfare and education support team for executives and employees, and allocating Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical. The specifics will be decided at the next Council meeting.
The board also discussed holding an extraordinary shareholders' meeting of Hanmi Pharmaceutical through a shareholders' proposal for Hanmi Science, which holds a 40% stake in Hanmi Pharmaceutical. At the extraordinary shareholders' meeting of Hanmi Pharmaceutical, the appointment of two outside directors, Im Jong-yoon, Im Jong-hoon, and Shin Dong-guk, will be proposed.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
